Joseph Haas

Joseph Haas

Senior Writer

Washington, DC

Joe has covered a wide range of biopharmaceutical stories since 2007 and contributes to Scrip, In Vivo, Pink Sheet and related Citeline publications. His specialties include business development, commercial strategies and liver and infectious diseases.

Latest from Joseph Haas

Viking Excites With Latest Oral VK2735 Weight Loss Data

Viking’s dual GLP-1/GIP agonist VK2735 continues to make headlines for strong efficacy and tolerability with oral and injectable formulations. CinFina reports progress with two new MOAs.

Novo Nordisk’s Semaglutide Hits Phase III Marks In NASH

The blockbuster GLP-1 analog demonstrated a capability for fibrosis reduction and disease resolution in the Phase III ESSENCE study. The firm plans to file for approval in 2025.

Madrigal Shatters Street Expectations With $62m In Q3 Rezdiffra Sales

Doubling some analyst projections for its second full quarter on market, Madrigal’s NASH drug appears headed to blockbuster status and a sustained market position.

AbbVie’s New Era: Skyrizi Sales Top Humira For First Time

Uptake in immunology, gastrointestinal and dermatology indications have enabled Skyrizi to post 51% year-over-year growth, and overtake sales for biosimilar-challenged stalwart Humira.

Crescent Jumps Into VEGFxPD-1 Bispecific Race Via Merger With GlycoMimetics

Troubled GlycoMimetics will merge with Crescent, bringing its PD-1- and VEGF-targeting bispecific CR-001 and gaining a public listing. Crescent also will raise $200m to help position itself against PD-1xVEGF leaders Akeso/Summit and BioNTech.

AbbVie Adds Alzheimer’s Opportunity With $1.4bn Aliada Buy

Aliada’s ALIA-1758 addresses the same target as Lilly’s Kisunla, but is paired with a blood-brain barrier transport technology that may offer high affinity and potential for lower dosing.